Anticancer agent 309
Anticancer agent 309 (Compound HZ-1) is an anticancer agent and G-quadruplex binder, with Kd values of 2.46 μM and 1.61 μM for c-Myc G4 and KRAS G4, respectively. Anticancer agent 309 promotes the formation of intranuclear G4. Anticancer agent 309 shows higher selectivity for parallel G4 than for non-parallel G4. Anticancer agent 309 inhibits the NRF2 signaling pathway and reduces the expression of XCT and GPX4. Anticancer agent 309 induces Ferroptosis, Apoptosis and immunogenic cell death in cells. Anticancer agent 309 exerts antitumor efficacy against breast cancer. Anticancer agent 309 is applicable for the research of breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C31H36N6
- Molecular Weight:492.66
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Anticancer agent 309 binds potently to purified c-Myc G4 and KRAS G4 structures, with Kd values of 2.46 μM and 1.61 μM, respectively[1].
Anticancer agent 309 (24 h) inhibits the proliferation of various human and mouse tumor cell lines (MDA-MB-231, HCT116, HepG2, A549, MCF-7, 4T1), with IC50 values ranging from 7.77 ± 0.77 μM to 16.71 ± 0.71 μM[1].
Anticancer agent 309 (10 μM; 24 h) promotes the formation of nuclear G4 in human breast cancer MDA-MB-231 cells[1].
Anticancer agent 309 (5-20 μM; 24 h) triggers apoptosis in breast cancer MDA-MB-231 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human breast cancer MDA-MB-231 cells, human colon cancer HCT116 cells, human liver cancer HepG2 cells, human lung cancer A549 cells, human breast cancer MCF-7 cells, mouse breast cancer 4T1 cells, human normal breast MCF-10a cells
-
Concentration:Titrated to determine IC50
-
Incubation Time:24 h
-
Result:Exerted dose-dependent cytotoxicity against all tested tumor cell lines, with IC50 values of 7.77 ± 0.77 μM (MDA-MB-231), 8.33 ± 0.46 μM (HCT116), 9.88 ± 1.18 μM (HepG2), 11.67 ± 0.33 μM (A549), 16.71 ± 0.71 μM (MCF-7), and 15.23 ± 0.95 μM (4T1).
Showed an IC50 of 28.12 ± 1.49 μM against normal MCF-10a cells, which was significantly higher than against tumor cells.
-
Cell Line:Human breast cancer MDA-MB-231 cells
-
Concentration:5-20 μM
-
Incubation Time:24 h
-
Result:Downregulated c-Myc and KRAS protein expression in a dose-dependent manner.
Suppressed the NRF2 signaling pathway, reducing the expression of XCT and GPX4.
Decreased the expression of Caspase 7, Caspase 3, and anti-apoptotic Bcl-2, while increased Cleaved Caspase 3 expression at 20 μM.
-
Cell Line:Human breast cancer MDA-MB-231 cells
-
Concentration:5-20 μM
-
Incubation Time:24 h
-
Result:Triggered a dose-dependent increase in both early apoptotic and late apoptotic cell populations.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 4 weeks old, subcutaneously inoculated with 4×105 4T1 mouse breast cancer cells)[1]
-
Dosage:10 mg/kg
-
Administration:every other day; 14 days
-
Result:Reduced final tumor weight.
Suppressed tumor growth.
Elevated percentage of CD45+CD3+CD4+ helper T cells in spleens and in tumors.
Elevated percentage of CD45+CD3+CD8+ cytotoxic T lymphocytes in spleens and in tumors.
Induced downregulation of GPX4 and upregulation of Cleaved Caspase 3 in tumor tissues.
Did not cause significant mouse weight loss or major organ weight changes relative to controls.
Chemical Information
-
Molecular Weight 492.66
-
Formel C31H36N6
-
SMILES
CN1CCN(CC1)C2=CC=C(C=C2)C3=C(NC(C4=CC=CC=C4)=N3)C5=CC=C(C=C5)N6CCN(CC6)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- Anticancer agent 309
- Anticancer agent309
- Anticancer agent-309
- G-quadruplex
- Keap1-Nrf2
- Ferroptosis
- Apoptosis
- ferroptosis
- parallel G-quadruplexes
- immunogenic cell death
- c-Myc G-quadruplex
- CD4+ helper T lymphocytes
- NRF2-XCT-GPX4 pathway
- apoptosis
- breast cancer cells
- KRAS G-quadruplex
- CD8+ cytotoxic T lymphocytes
- Inhibitor
- inhibitor
- inhibit